Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement
- PMID: 23071261
- PMCID: PMC3513650
- DOI: 10.1158/1078-0432.CCR-11-3150
Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement
Abstract
The Rad52 protein was largely ignored in humans and other mammals when the mouse knockout revealed a largely "no-effect" phenotype. However, using synthetic lethal approaches to investigate context-dependent function, new studies have shown that Rad52 plays a key survival role in cells lacking the function of the breast cancer type 1 susceptibility protein (BRCA1)-BRCA2 pathway of homologous recombination. Biochemical studies also showed significant differences between yeast and human Rad52 (hRad52), in which yeast Rad52 can promote strand invasion of replication protein A (RPA)-coated single-stranded DNA (ssDNA) in the presence of Rad51 but hRad52 cannot. This results in the paradox of how is hRad52 providing Rad51 function: presumably there is something missing in the biochemical assays that exists in vivo, but the nature of this missing factor is currently unknown. Recent studies have suggested that Rad52 provides back-up Rad51 function for all members of the BRCA1-BRCA2 pathway, suggesting that Rad52 may be a target for therapy in BRCA pathway-deficient cancers. Screening for ways to inhibit Rad52 would potentially provide a complementary strategy for targeting BRCA-deficient cancers in addition to poly (ADP-ribose) polymerase (PARP) inhibitors.
©2012 AACR.
Conflict of interest statement
The authors have no potential conflict of interest to report.
Figures
Similar articles
-
RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10. Oncogene. 2013. PMID: 22964643 Free PMC article.
-
Replication Protein A Phosphorylation Facilitates RAD52-Dependent Homologous Recombination in BRCA-Deficient Cells.Mol Cell Biol. 2022 Feb 17;42(2):e0052421. doi: 10.1128/mcb.00524-21. Epub 2021 Dec 20. Mol Cell Biol. 2022. PMID: 34928169 Free PMC article.
-
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8. Blood. 2013. PMID: 23836560 Free PMC article.
-
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.Cold Spring Harb Perspect Biol. 2015 Apr 1;7(4):a016600. doi: 10.1101/cshperspect.a016600. Cold Spring Harb Perspect Biol. 2015. PMID: 25833843 Free PMC article. Review.
-
Therapeutic exploitation of tumor cell defects in homologous recombination.Anticancer Agents Med Chem. 2008 May;8(4):448-60. doi: 10.2174/187152008784220267. Anticancer Agents Med Chem. 2008. PMID: 18473729 Review.
Cited by
-
Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction.PLoS One. 2021 Mar 30;16(3):e0248941. doi: 10.1371/journal.pone.0248941. eCollection 2021. PLoS One. 2021. PMID: 33784323 Free PMC article.
-
Dynamic Modelling of DNA Repair Pathway at the Molecular Level: A New Perspective.Front Mol Biosci. 2022 Sep 13;9:878148. doi: 10.3389/fmolb.2022.878148. eCollection 2022. Front Mol Biosci. 2022. PMID: 36177351 Free PMC article.
-
Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52-ssDNA association.RSC Adv. 2018 May 23;8(34):18859-18869. doi: 10.1039/c8ra01919c. eCollection 2018 May 22. RSC Adv. 2018. PMID: 35539677 Free PMC article.
-
Human somatic cells deficient for RAD52 are impaired for viral integration and compromised for most aspects of homology-directed repair.DNA Repair (Amst). 2017 Jul;55:64-75. doi: 10.1016/j.dnarep.2017.04.006. Epub 2017 May 10. DNA Repair (Amst). 2017. PMID: 28549257 Free PMC article.
-
Functional characterization of RAD52 as a lung cancer susceptibility gene in the 12p13.33 locus.Mol Carcinog. 2016 May;55(5):953-63. doi: 10.1002/mc.22334. Epub 2015 May 27. Mol Carcinog. 2016. PMID: 26013599 Free PMC article.
References
-
- Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. [Internet] [cited 2012 Apr 23];Science (New York, N.Y.) 1995 Jun;268(5218):1749–1753. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7792600. - PubMed
-
- Stewart GS, Maser RS, Stankovic T, Bressan DA, Kaplan MI, Jaspers NG, et al. [Internet] [cited 2012 Apr 23];Cell. 1999 Dec;99(6):577–587. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10612394. - PubMed
-
- Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. [Internet] Nature reviews. Cancer. 2012 Jan;12(1):68–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22193408. - PMC - PubMed
-
- Symington LS. Role of RAD52 Epistasis Group Genes in Homologous Recombination and Double-Strand Break Repair [Internet] Microbiology and Molecular Biology Reviews. 2002;66(4):630–670. table of contents.Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=134659&tool=pm.... - PMC - PubMed
-
- McEachern MJ, Haber JE. Break-induced replication and recombinational telomere elongation in yeast. [Internet] [cited 2012 Mar 16];Annual review of biochemistry. 2006 Jan;75:111–135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16756487. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials
Miscellaneous